PHARVARIS NV
PHVSNASDAQTrading Snapshot
- Day Range
- $34.17 – $34.79
- 52-Week Range
- —
- Volume
- $2.95B
- Avg Volume
- $2.23B
- Shares Outstanding
- 69.7M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $890M
- Last Q Revenue
- $248M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own PHVS
- ✓High-growth profile — revenue up +0.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 69% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PHARVARIS NV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment
Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both immediate-release. Find out why PHVS stock is a buy.
Pharvaris (PHVS) Stock May Be Pricey After A 103% Five Year Run
Pharvaris stock has delivered a strong 103.0% return over the past five years, yet the latest valuation checks and market multiples suggest the shares may now sit on the expensive side rather than offering clear value. Over the last 5 years Pharvaris has returned 103.0%, which sets a high bar for any further upside to be justified by fundamentals. Future growth in revenue and cash flow can support the current price, but execution risk around turning that growth into sustainable profitability...
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet
The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains.
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet need
Pharvaris Announces Publication Of Comprehensive Review On Bradykinin Biology And B2R Antagonism In Clinical Reviews In Allergy & Immunology
Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for targeting the bradykinin B2